Effect of the COVID-19 pandemic on diagnoses and therapy of head and neck squamous cell carcinoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031558

Enrollment

20000

Registered

2023-03-27

Start date

2023-05-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C00-C14 C32 C76.0 C76.7 C76.8

Interventions

Group 1: COVID-19 cohort - patients who were diagnosed with head and neck squamous cell carcinoma (HNSCC) between January 2020 and December 2021. The incidence, tumor stage, primary treatment method,

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Head and neck squamous cell carcinoma (HNSCC)

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Incidence of newly diagnosed head and neck squamous cell carcinoma (HNSCC)	—

Secondary

Measure	Time frame
Tumour stage, primary treatment modality, time interval between diagnosis and initiation of tumour therapy.	—

Countries

Germany

Contacts

Public ContactConstantin Hintschich

Klinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde, Universitätsklinikum Regensburg

constantin.hintschich@ukr.de+499419449410

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026